

Dear Friends and Protagen Collaborators,

We hope you had a relaxing and refreshing summertime and were able to take some holidays as well. During this 3rd Quarter we built upon our recent milestones and expanded our assay development activities, which will result in several new product releases over the coming weeks and months. We are also very excited about newly initiated research efforts and pharma collaborations in the field of Sjögren's disease, a new indication for us with high unmet diagnostic and medical need. We will keep you informed of our progress and look forward to connecting with you soon.



Multilisa SSc Gearing up for Market Launch



Our Multilisa[®] SSc (Systematic Sclerosis) development program is far advanced by now and we are gearing up for market launch. We are particularly excited about our Multilisa[®] BICD2 assay. This is our first proprietary marker that will be commercialized and with a prevalence of 30% in SSc patients, we are proud to state that it is the 3rd most prevalent marker in SSc today. Its presence is also a negative predictive value for pulmonary fibrosis in SSc and there is also a clear medical claim that is associated with this marker which makes us even more proud of it.

Conferences & Meet us @



In September, we attended the **Lupus conference** in Vienna, the **DGRh meeting** in Bremen, and the Dresden **Symposium on autoantibodies**. We expanded our network to KOLs and generated new business opportunities with pharma and biotech. In the next Quarter, we will attend the **BioInvestor Forum** in San Francisco and the **American College of Rheumatology (ACR) meeting**, also held in San Francisco. We invite you to join and look forward to meeting with you there.

Corporate News & PR



We continued our PR and marketing efforts with profiles in Going Public and German Biotech Guide 2016. We issued a **whitepaper** on the current status of the autoimmune diagnostics market. Our publications and interviews in business magazines were mainly focused on NavigAID SLE and the company's potential to re-define the autoimmune landscape with new Dx. Resulting editorials, articles and interviews have appeared and more are due to appear soon.

Quartely Update

The summer has flown by and as we look back at yet another busy and eventful Quarter. We advanced our Multilisa[®] SSc program and initiated our 2nd IVD product line, the Multilisa[®] SLE, which is expected to be launched by the end of 2016.

During the 12th Dresden Symposium on Autoantibodies we hosted a Session on "The challenges to fill diagnostic gaps in Autoimmune Diseases", which featured Prof. Schneider from the HHU, Düsseldorf. We presented all our current development programs to an international audience from

science and industry. Their feedback reception was overwhelmingly positive and confirmed that the Protagen philosophy of developing novel biomarkers and simultaneously reducing the time to market is addressing the major growth hurdles in this market.

News

Protagen goes Social

As part of our social media development, our LinkedIn account and additional showcase pages were set-up and we are now actively communicating with you via LinkedIn. If you want to learn more please visit our [LinkedIn Company pages](#).

Protagen is Launch Partner of Deutsche Börse Venture Network

Deutsche Börse (German Stock Exchange) **Venture Network** connects companies and investors and so effectively helps improve the funding situation for high-growth companies such as Protagen.

Finally – Autumn Time

The autumn is here and the kite season has started. Great fun for kids and parents alike, but did you know that recreational kites were flown in the 1600s? A book that dates back to 1618 showing children flying diamond shaped kites, proves this. It goes to show that we may be able to learn from the past to build our new kites and impress our kids. We wish you a lot of fun!

